白芍总苷联合柳氮磺胺吡啶治疗强直性脊柱炎的疗效观察

目的观察白芍总苷联合柳氮磺胺吡啶治疗强直性脊柱炎的疗效和安全性。方法 42例符合强直性脊柱炎的标准的患者随机分为治疗组22例和对照组20例,治疗组口服白芍总苷和柳氮磺胺吡啶,对照组口服柳氮磺胺吡啶,两组均给予消炎止痛药物,疗程为6个月。结果经过6个月的治疗,两组间的晨僵持续时间、血沉、C反应蛋白、胸廓扩张度、Schober实验等指标方面较治疗前均明显降低,两组之间的晨僵持续时间、血沉、C反应蛋白的差别具有显著意义。治疗组不良反应的发生率明显小于对照组。结论白芍总苷联合柳氮磺胺吡啶治疗AS具有疗效确切不良反应小等优点,在临床有推广意义。     

The x c − cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine

Purpose  To determine whether the x_c⁻ cystine transporter could be a useful therapeutic target for small-cell lung cancer (SCLC). Methods  Human SCLC cell cultures were examined for growth dependence on extracellular cystine, x_c⁻ expression, glutathione levels and response to highly specific x_c⁻ inhibitors, i.e., monosodium glutamate (MSG) and the anti-inflammatory drug, sulfasalazine (SASP). In studying tumor growth inhibition by SASP, use was also made of a novel SCLC tissue xenograft model, LU6-SCLC, derived from a chemoresistant patient’s SCLC specimen. Results  Growth of NCI-H69 and NCI-H82 SCLC cells greatly depended on x_c⁻-mediated uptake of cystine. SASP substantially reduced their glutathione levels (>70%; 0.3 mM SASP; 24 h) and growth (72 h) with IC₅₀s of 0.21 and 0.13 mM, respectively; MSG also inhibited growth markedly. Both SASP- and MSG-induced growth arrests were largely prevented by cystine uptake-enhancing 2-mercaptoethanol (66 μM) indicating they were primarily due to cystine starvation. Without major side-effects, SASP (i.p.) restrained growth of NCI-H69 cell xenografts (~50%) and, importantly, substantially inhibited growth of the clinically more relevant LU6-SCLC tissue xenografts (~70% by stereological analysis), reducing tumor glutathione contents. Conclusions  The x_c⁻ cystine/glutamate antiporter is potentially useful as a target for therapy of SCLC based on glutathione depletion. Sulfasalazine may be readily used for this approach, especially in combination chemotherapy.     

Inhibition of breast cancer-cell glutamate release with sulfasalazine limits cancer-induced bone pain

Cancer in bone is frequently a result of metastases from distant sites, particularly from the breast, lung, and prostate. Pain is a common and often severe pathological feature of cancers in bone, and is a significant impediment to the maintenance of quality of life of patients living with bone metastases. Cancer cell lines have been demonstrated to release significant amounts of the neurotransmitter and cell-signalling molecule l-glutamate via the system x_C⁻ cystine/glutamate antiporter. We have developed a novel mouse model of breast cancer bone metastases to investigate the impact of inhibiting cancer cell glutamate transporters on nociceptive behaviour. Immunodeficient mice were inoculated intrafemorally with the human breast adenocarcinoma cell line MDA-MB-231, then treated 14 days later via mini-osmotic pumps inserted intraperitoneally with sulfasalazine, (S)-4-carboxyphenylglycine, or vehicle. Both sulfasalazine and (S)-4-carboxyphenylglycine attenuated in vitro cancer cell glutamate release in a dose-dependent manner via the system x_C⁻ transporter. Animals treated with sulfasalazine displayed reduced nociceptive behaviours and an extended time until the onset of behavioural evidence of pain. Animals treated with a lower dose of (S)-4-carboxyphenylglycine did not display this reduction in nociceptive behaviour. These results suggest that a reduction in glutamate secretion from cancers in bone with the system x_C⁻ inhibitor sulfasalazine may provide some benefit for treating the often severe and intractable pain associated with bone metastases.     

柳氮磺吡啶肠溶胶囊释放度的测定

用转筛法测定柳氮磺吡啶肠胶囊的释放度。结果表明,该制剂在盐酸溶液中２ｈ无药物释出,在ＰＨ６．８的磷酸盐缓冲液中３ｈ有小于１０％的药物释出,在ＰＨ７．８的磷酸盐缓冲液中１５ｍｉｎ释放５０％、４５ｍｉｎ释放８５％以上,达到结肠靶向给药的目的。     

中药灌肠结合柳氮磺胺吡啶对溃疡性结肠炎的效果观察

目的探讨中药灌肠结合柳氮磺胺吡啶在溃疡性结肠炎治疗中的应用效果。方法2013年1月～2015年1月间收治的溃疡性结肠炎患者34例，采用随机数字表法分为对照组（17例，给予柳氮磺胺吡啶治疗）和观察组（17例，加用中药红金丹灌肠），比较两组临床效果。结果观察组总有效率高于对照组，治疗后患者IFN-γ、IL-4水平及DAI评分改善情况优于对照组，差异有统计学意义（P＜0.05）。结论溃疡性结肠炎治疗中应用中药灌肠结合柳氮磺胺吡啶可有效提高治疗效果。     

益赛普、柳氮磺砒碇治疗强直性脊柱炎对照研究

目的 通过与柳氮磺砒啶（SSZ）进行对照,研究益赛普对强直性脊柱炎（AS）的疗效.方法 选取处于活动期的AS患者40例,分别给予益赛普（50 mg/周）及柳氮磺砒碇（2.0g/日）进行治疗,总疗程为24周,对两药在12、24周时疗效及观察指标进行评估.结果 益赛普在12、24周时的有效率分别为90.0%,95.0%,柳氮磺吡啶都为70.0%.显示益赛普能显著改善临床实验观察指标（P〈0.05）,耐受性与柳氮磺吡啶差异无显著性（P〉0.5）. 结论益赛普是一种新型有效且安全的治疗AS的药物.     

柴胡桂枝汤治疗克罗恩病的临床疗效分析

目的探讨分析柴胡桂枝汤治疗克罗恩病的临床疗效。方法收集48例克罗恩病患者,将其随机分为观察组与对照组,每组各24例。对照组患者采用柳氮磺吡啶治疗,观察组在对照组基础上加用柴胡桂枝汤治疗。观察两组疗程并随访半年,比较两组患者临床疗效、免疫功能变化、不良反应、治疗有效时间及复发情况。结果观察组临床有效率为91.67%,明显优于对照组的66.67%（P〈0.05）;观察组免疫功能变化明显优于对照组（P〈0.05）;观察组不良反应及并发症发生率分别为8.33%和12.50%,明显少于对照组的37.50%和41.67%（P〈0.05）;观察组平均治疗有效时间明显短于对照组（P〈0.05）;观察组复发率（4.17%）明显低于对照组（25.00%）（P〈0.05）。结论柴胡桂枝汤治疗克罗恩病效果肯定,可显著提高临床疗效,缩短疗程,增加患者免疫力,减少不良反应及并发症,降低复发率,临床值得推广应用     

联用补脾益肠丸和柳氮磺吡啶治疗溃疡性结肠炎的临床观察

目的探讨应用补脾益肠丸和柳氮磺胺吡啶合用治疗溃疡性结肠炎的效果。方法选择2006年1月至2009年11月来我院就诊的溃疡性结肠炎患者218例,随机分为两组,治疗组服用补脾益肠丸和柳氮磺吡啶片治疗;对照组服用柳氮磺胺吡啶片。结果治疗组总有效率96．33％,对照组总有效率87．16％,治疗组明显优于对照组。结论补脾益肠丸联用柳氮磺吡啶片治疗渍疡性结肠炎疗效好,副作用小,值得临床推广。     

雷公藤口服液在治疗强直性脊柱炎中的应用

目的:观察雷公藤口服液(LOS)联合氯诺昔康(LOR)、柳氮磺嘧啶(SSZ)和甲氨蝶呤(MTX)治疗强直性脊柱炎(AS)的临床效果和安全性。方法:116例符合强直性脊柱炎标准的患者随机分为2组:治疗组:58例,口服LOS+LOR+SSZ+MTX;对照组:58例,口服LOR+SSZ+MTX。2组疗程均为3个月。结果:经过3个月的治疗,2组腰背痛指数、晨僵持续时间、胸廓活动度、Schober实验、血沉(ESR)及C反应蛋白(CRP)等6项指标较治疗前均显著降低(P<0.05或P<0.01),且治疗组上述指标改善值优于对照组,差异有统计学意义(P<0.05);2组治疗后不良反应发生率比较差异无统计学意义(P>0.05);X线片比较,治疗组无变化56例,对照组无变化50例,组间比较,差异有统计学意义(P<0.01)。结论:雷公藤口服液联合氯诺昔康、柳氮磺嘧啶和甲氨蝶呤是治疗强直性脊柱炎安全有效的方法。